Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

Exclusion Criteria

• •1. Decompensated cirrhosis or Model for End Stage Liver Disease score \> 13.
• •2. Modified Nazer score \> 7.
• •3. Clinically significant gastrointestinal bleed within past 3 months.
• •4. Alanine aminotransferase \> 2 × upper limit of normal.
• •5. History of bleeding abnormality or known coagulopathy, including platelet count \< 100,000, and international normalized ratio for prothrombin time ≥ 1.5.
• •6. Participant unwilling to accept blood products, if required.
• •7. Marked neurological disease requiring either nasogastric feeding tube or intensive inpatient medical care.
• •8. Hemoglobin less than lower limit of the reference range for age and sex.
• •9. Participants in renal failure, defined as in end-stage renal disease on dialysis (chronic kidney disease 5) or creatinine clearance \< 30 milliliters/minute.
• •10. Lymphoma, leukemia, or any malignancy within the past 5 years.
• •11. Current or chronic history of liver disease not associated with WD.